Neurocrine Secures FDA Approval of Ingrezza's Sprinkle Capsules

The US FDA endorsed the utilization of a sprinkle case plan of Neurocrine Biosciences Ingrezza (valbenazine) for the treatment of tardive dyskinesia and chorea in Huntington's illness. The US FDA endorsed the utilization of a sprinkle case plan.....

Astellas and Poseida Ink Pact To Develop Novel Allogeneic Cell Therapies

Japanese Astellas Pharma Inc. and Poseida Therapeutics, Inc. declared that Xyphos Biosciences, Inc., and Poseida have gone into a research collaboration and permit consent to foster novel convertibleCAR® programs by consolidating the creative cell...

TriLink BioTech and Lonza Foray into Non-exclusive Supply Agreement

TriLink BioTechnologies, a Maravai LifeSciences company that provides global life science reagents and services, has signed a non-exclusive License and Supply Agreement with Lonza, an international development and manufacturing partner for the...

Bio-Techne Forays Distribution Agreement with Thermo Fisher Scientific

Bio-Techne Enterprise, a biotechnology firm, declare a critical achievement in its obligation to giving state of the art solutions for its users. With effective from May 1, 2024, the firm will foray into an strategic distribution deal with Thermo...

Ono Pharma To Acquire US Drugmaker Deciphera For USD 2.4 Billion

Ono Pharmaceutical, a leading Japanese pharma firm, intends to make its largest acquisition to date, purchasing an American cancer drug manufacturer for $2.4 billion. The company is looking for growth through new drug candidates As the Opdivo...

Maruti Suzuki successfully completes a pilot program of First Responder training in association with AIIMS and IRF on Emergency Care

Strengthening its road safety initiatives, Maruti Suzuki India Limited had partnered with AIIMS, India’s premier medical institute, and International Road Federation (IRF) to provide first aid and trauma care training to commercial drivers

American Oncology Institute (AOI) in Mangalagiri Pioneers Innovative Approach in Breast Cancer Surgery for High-Risk Patients

American Oncology Institute (AOI) in Mangalagiri proudly announces a groundbreaking advancement in the treatment of breast cancer. Recently, AOI successfully treated three high-risk patients with carcinoma breast

US FDA Nods X4 Pharmaceutical's Therapy For Immunodeficiency Disease

The US FDA has approved its treatment for patients over 12 with a rare genetic immunodeficiency disease, per X4 Pharmaceuticals. X4's mavorixafor, to be sold under the brand name Xolremdi, is the primary treatment to get U.S. endorsement...

Manipal Hospitals Acquires Majority Stake in Medica Synergie

Manipal Hospitals, a leading multispeciality hospital, added that it is gaining an 87% stake in Kolkata-based clinic chain Medica Synergie in a contract that industry sources said is expected to be worth an expected ₹1,400 crore...

Yokogawa Helps to Revolutionize the Field of Single-Cell Lipidomics

Yokogawa Electric Corporation’s latest single-cell analysis solution, the Single Cellome™ System SS2000, has been featured in an article published in the high-profile journal Analytical Chemistry

© 2024 India Pharma Outlook. All Rights Reserved.